• Explore /
  • Poster
  • / Real-world trends in EU4 and the UK in frontline (1L) maintenance (MT) for nonsquamous (NSQ) advanced non-small cell lung cancer (aNSCLC) without actionable mutations after introduction of immune checkpoint inhibitors.

Real-world trends in EU4 and the UK in frontline (1L) maintenance (MT) for nonsquamous (NSQ) advanced non-small cell lung cancer (aNSCLC) without actionable mutations after introduction of immune checkpoint inhibitors.

Abstract Video & Slides Poster

Authors

null

Cosmina Hogea

Global Value, Evidence and Outcomes Oncology, GlaxoSmithKline, Philadelphia, PA

Cosmina Hogea, Linda Kalilani, Jasjit Multani, Vicky Casey, Sheila Mpima, Marie Yasuda, Chi-Chang Chen, Fil Manguid, Thomas J. Giove, Jessica Chao, Amine Aziez, Alexander Stojadinovic

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care

Track

Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities

Sub Track

Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 28; abstr 296)

DOI

10.1200/JCO.2020.39.28_suppl.296

Abstract #

296

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nikhil Shukla

First Author: Panpan Zhang

First Author: Melissa Lynne Johnson

First Author: Stephen V. Liu